S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:HCM

HUTCHMED (HCM) Stock Price, News & Analysis

$16.80
-0.05 (-0.30%)
(As of 03/28/2024 ET)
Today's Range
$16.69
$17.05
50-Day Range
$12.08
$18.56
52-Week Range
$10.68
$20.73
Volume
62,060 shs
Average Volume
121,278 shs
Market Capitalization
$2.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.70

HUTCHMED MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
76.8% Upside
$29.70 Price Target
Short Interest
Bearish
0.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of HUTCHMED in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to $0.63 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

Medical Sector

746th out of 938 stocks

Pharmaceutical Preparations Industry

335th out of 420 stocks

HCM stock logo

About HUTCHMED Stock (NASDAQ:HCM)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HCM Stock Price History

HCM Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at StockNews.com
HUTCHMED (NASDAQ:HCM) Shares Down 5%
Hutchmed Is Turning Profitable
HUTCHMED (NASDAQ:HCM) Downgraded by StockNews.com
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
HCM Mar 2024 17.500 call
HUTCHMED (China) Limited (0013.HK)
See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HCM
Employees
1,988
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$29.70
High Stock Price Target
$50.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+76.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$838 million
Cash Flow
$0.63 per share
Book Value
$4.27 per share

Miscellaneous

Free Float
167,978,000
Market Cap
$2.93 billion
Optionable
Not Optionable
Beta
0.80

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Wei-Guo Su B.Sc. (Age 65)
    Ph.D., CEO, Chief Scientific Officer & Executive Director
    Comp: $2.45M
  • Mr. Chig Fung Cheng BEc (Age 57)
    CA, CFO & Executive Director
    Comp: $962.15k
  • Ms. Edith Shih BSE (Age 72)
    C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E, Company Secretary & Non-Executive Director
  • Dr. Karen Jane Atkin (Age 58)
    Executive VP & COO
  • David Ng
    Head of Investor Relations & Capital Strategies
  • Mr. Charles George Rupert Nixon (Age 54)
    Group General Counsel
  • Mr. Kin Hung Lee M.B.A. (Age 47)
    Senior Vice President of Corporate Management & Communications
  • Ms. Selina Zhang
    Senior Vice President of Global Human Resources
  • Dr. Qingmei Wang Ph.D. (Age 61)
    Senior Vice President of Business Development & Strategic Alliances
  • Mr. Hong Chen (Age 54)
    Senior VP & Chief Commercial Officer- China

HCM Stock Analysis - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCM shares.
View HCM analyst ratings
or view top-rated stocks.

What is HUTCHMED's stock price target for 2024?

4 equities research analysts have issued 1-year price objectives for HUTCHMED's stock. Their HCM share price targets range from $17.00 to $50.00. On average, they anticipate the company's share price to reach $29.70 in the next twelve months. This suggests a possible upside of 76.8% from the stock's current price.
View analysts price targets for HCM
or view top-rated stocks among Wall Street analysts.

How have HCM shares performed in 2024?

HUTCHMED's stock was trading at $18.11 on January 1st, 2024. Since then, HCM shares have decreased by 7.2% and is now trading at $16.80.
View the best growth stocks for 2024 here
.

When is HUTCHMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our HCM earnings forecast
.

What ETFs hold HUTCHMED's stock?

ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

HUTCHMED (HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Schroder Investment Management Group (2.40%), Allianz Asset Management GmbH (0.89%), Bellevue Group AG (0.65%), Goldman Sachs Group Inc. (0.27%), Goldman Sachs Group Inc. (0.27%) and Hsbc Holdings PLC (0.12%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HCM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners